Walsh Colin
- SEC CIK
- 0001866174
No open-market purchases or sales filed in the past year.
Current role at each company
- ATTO Attovia Therapeutics, Inc.Directoras of Aug 28, 2026
- Elevation Oncology, Inc.Directoras of Jun 21, 2023
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists Walsh Colin as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
ATTO Attovia Therapeutics, Inc.
Director3 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 28, 2026 (view filing)5:38 PM ET | Aug 5-6 | 23 days | Walsh ColinDirector | PPurchase | +585.0K | $17.58 | +$10.3M | +24.0%3.02M after | Amended2 lotsDuplicate filing |
| Aug 28, 2026 (view filing)5:38 PM ET | Aug 5 | 23 days | Walsh ColinDirector | SSale | −105.8K | $21.28 | −$2.25M | −100.0%0 after | Amended23 lotsDuplicate filing |
| Aug 28, 2026 (view filing)5:38 PM ET | Aug 5 | 23 days | Walsh ColinDirector | PPurchase | +105.8K | $21.25 | +$2.25M | –105.8K after | AmendedDerivative6 lotsDuplicate filing |